FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200076307> ?p ?o ?g. }

• W4200076307 abstract "Introduction: optimal treatment of Gram-negative infections in critically ill patients is challenged by changing pathophysiological conditions, reduced antimicrobial susceptibility and limited therapeutic options. The aim of this study was to assess the impact of maximizing Css/MIC ratio on efficacy of continuous infusion (CI) meropenem in treating documented Gram-negative infections in critically ill patients and to perform a population pharmacokinetic/pharmacodynamic analysis to support treatment optimization. Materials and Methods: Classification and regression tree (CART) analysis was used to identify whether a cutoff of steady-state meropenem concentration (Css)-to-minimum inhibitory concentration (MIC) (Css/MIC) ratio correlated with favorable clinical outcome. A non-parametric approach with Pmetrics was used for pharmacokinetic analysis and covariate evaluation. The probability of target attainment (PTA) of the identified Css/MIC ratio was calculated by means of Monte Carlo simulations. Cumulative fraction of response (CFRs) were calculated against common Enterobacterales, P. aeruginosa and A. baumannii as well. Results: a total of 74 patients with 183 meropenem Css were included. CART analysis identified a Css/MIC ratio ≥4.63 as cutoff value significantly associated with favorable clinical outcomes. Multivariate regression analysis confirmed the association [OR (95%CI): 20.440 (2.063–202.522); p &lt; 0.01]. Creatinine clearance (CL CR ) was the only covariate associated with meropenem clearance. Monte Carlo simulations showed that, across different classes of renal function, dosages of meropenem ranging between 0.5 and 2 g q6h over 6 h (namely by CI) may grant PTAs of Css/MIC ratios ≥4.63 against susceptible pathogens with an MIC up to the EUCAST clinical breakpoint of 2 mg/L. The CFRs achievable with these dosages were very high (&gt;90%) against Enterobacterales across all the classes of renal function and against P. aeruginosa among patients with CL CR &lt; 30 ml/min/1.73 m 2 , and quite lower against A. baumannii . Discussion: our findings suggest that Css/MIC ratio ≥4.63 may be considered the pharmacodynamic target useful at maximizing the efficacy of CI meropenem in the treatment of Gram-negative infections in critically ill patients. Dosages ranging between 0.5 g q6h and 2 g q6h by CI may maximize the probability of favorable clinical outcome against meropenem-susceptible Gram-negative pathogens among critically ill patients having different degrees of renal function ." @default.
• W4200076307 created "2021-12-31" @default.
• W4200076307 creator A5011194090 @default.
• W4200076307 creator A5012239760 @default.
• W4200076307 creator A5013635469 @default.
• W4200076307 creator A5030193021 @default.
• W4200076307 creator A5038157846 @default.
• W4200076307 creator A5040568455 @default.
• W4200076307 creator A5045135007 @default.
• W4200076307 creator A5061400936 @default.
• W4200076307 creator A5061691353 @default.
• W4200076307 creator A5071687756 @default.
• W4200076307 date "2021-12-08" @default.
• W4200076307 modified "2023-10-13" @default.
• W4200076307 title "Impact of Maximizing Css/MIC Ratio on Efficacy of Continuous Infusion Meropenem Against Documented Gram-Negative Infections in Critically Ill Patients and Population Pharmacokinetic/Pharmacodynamic Analysis to Support Treatment Optimization" @default.
• W4200076307 cites W1955799584 @default.
• W4200076307 cites W1969500929 @default.
• W4200076307 cites W2017947220 @default.
• W4200076307 cites W2021298363 @default.
• W4200076307 cites W2093073135 @default.
• W4200076307 cites W2097898411 @default.
• W4200076307 cites W2102663241 @default.
• W4200076307 cites W2117538827 @default.
• W4200076307 cites W2118905287 @default.
• W4200076307 cites W2132112261 @default.
• W4200076307 cites W2148103762 @default.
• W4200076307 cites W2155965977 @default.
• W4200076307 cites W2160331061 @default.
• W4200076307 cites W2165839757 @default.
• W4200076307 cites W2294833633 @default.
• W4200076307 cites W2298261704 @default.
• W4200076307 cites W2335959320 @default.
• W4200076307 cites W2584388311 @default.
• W4200076307 cites W2766636752 @default.
• W4200076307 cites W2773548512 @default.
• W4200076307 cites W2786886659 @default.
• W4200076307 cites W2790726559 @default.
• W4200076307 cites W2884031449 @default.
• W4200076307 cites W2887854709 @default.
• W4200076307 cites W2892368225 @default.
• W4200076307 cites W2903594559 @default.
• W4200076307 cites W2929478224 @default.
• W4200076307 cites W2963222371 @default.
• W4200076307 cites W2975920332 @default.
• W4200076307 cites W2982416482 @default.
• W4200076307 cites W3012868903 @default.
• W4200076307 cites W3022327571 @default.
• W4200076307 cites W3042253385 @default.
• W4200076307 cites W3092173712 @default.
• W4200076307 cites W3094338265 @default.
• W4200076307 cites W3106009346 @default.
• W4200076307 cites W3175189556 @default.
• W4200076307 cites W3194223471 @default.
• W4200076307 cites W3195627102 @default.
• W4200076307 cites W4226277588 @default.
• W4200076307 doi "https://doi.org/10.3389/fphar.2021.781892" @default.
• W4200076307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34955851" @default.
• W4200076307 hasPublicationYear "2021" @default.
• W4200076307 type Work @default.
• W4200076307 citedByCount "10" @default.
• W4200076307 countsByYear W42000763072021 @default.
• W4200076307 countsByYear W42000763072022 @default.
• W4200076307 countsByYear W42000763072023 @default.
• W4200076307 crossrefType "journal-article" @default.
• W4200076307 hasAuthorship W4200076307A5011194090 @default.
• W4200076307 hasAuthorship W4200076307A5012239760 @default.
• W4200076307 hasAuthorship W4200076307A5013635469 @default.
• W4200076307 hasAuthorship W4200076307A5030193021 @default.
• W4200076307 hasAuthorship W4200076307A5038157846 @default.
• W4200076307 hasAuthorship W4200076307A5040568455 @default.
• W4200076307 hasAuthorship W4200076307A5045135007 @default.
• W4200076307 hasAuthorship W4200076307A5061400936 @default.
• W4200076307 hasAuthorship W4200076307A5061691353 @default.
• W4200076307 hasAuthorship W4200076307A5071687756 @default.
• W4200076307 hasBestOaLocation W42000763071 @default.
• W4200076307 hasConcept C111113717 @default.
• W4200076307 hasConcept C112705442 @default.
• W4200076307 hasConcept C126322002 @default.
• W4200076307 hasConcept C159641895 @default.
• W4200076307 hasConcept C176947019 @default.
• W4200076307 hasConcept C2779375183 @default.
• W4200076307 hasConcept C2908647359 @default.
• W4200076307 hasConcept C501593827 @default.
• W4200076307 hasConcept C71924100 @default.
• W4200076307 hasConcept C86803240 @default.
• W4200076307 hasConcept C89423630 @default.
• W4200076307 hasConcept C94665300 @default.
• W4200076307 hasConcept C98274493 @default.
• W4200076307 hasConcept C99454951 @default.
• W4200076307 hasConceptScore W4200076307C111113717 @default.
• W4200076307 hasConceptScore W4200076307C112705442 @default.
• W4200076307 hasConceptScore W4200076307C126322002 @default.
• W4200076307 hasConceptScore W4200076307C159641895 @default.
• W4200076307 hasConceptScore W4200076307C176947019 @default.
• W4200076307 hasConceptScore W4200076307C2779375183 @default.
• W4200076307 hasConceptScore W4200076307C2908647359 @default.
• W4200076307 hasConceptScore W4200076307C501593827 @default.
• W4200076307 hasConceptScore W4200076307C71924100 @default.
• W4200076307 hasConceptScore W4200076307C86803240 @default.
• W4200076307 hasConceptScore W4200076307C89423630 @default.

• next